The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Preclinical and clinical development of siRNA-based therapeutics
Open accessAbstract
Discovery of RNA interference, first in plants and C. elegans and later in mammalian cells, led to the emergence of a transformative view in biomedical research. Knowledge of the multiple actions of non-coding RNAs has truly allowed viewing DNA, RNA and proteins in novel ways. Small interfering RNAs (siRNAs) can be used as tools to study single gene function both in vitro and in vivo and are an attractive new class of therapeutics, especially against undruggable targets for the treatment of cancer and other diseases. Despite the potential of siRNAs in cancer therapy, many challenges remain, including rapid degradation, poor cellular uptake and off-target effects. Rational design strategies, selection algorithms, chemical modifications and nanocarriers offer significant opportunities to overcome these challenges. Here, we review the development of siRNAs as therapeutic agents from early design to clinical trial, with special emphasis on the development of EphA2-targeting siRNAs for ovarian cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Long Noncoding RNAs: Cellular Address Codes in Development and Disease
Batista, P. J., & Chang, H. Y. (2013) · Cell · doi:10.1016/j.cell.2013.02.012 · Cited by 2,531
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Chargaff, E., & Davidson, J. N. (1955) · Cited by 2,043
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357 · cited 2×
“N,N,N acetylgalactosamine; IVT, intravitreal; LNAs, locked nuclei acid; PS, phosphorothioate; SLN, solid-lipid nanoparticles; ☆ This review is part of the Advanced Drug Delivery Rev ☆☆ The authors have no conflicts to report.”
Doench, J. G., Petersen, C. P., & Sharp, P. A. (2003) · Genes & Development · doi:10.1101/gad.1064703 · Cited by 1,260
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Post-transcriptional gene silencing by double-stranded RNA
Hammond, S. M., Caudy, A. A., & Hannon, G. J. (2001) · Nature Reviews Genetics · doi:10.1038/35052556 · Cited by 850
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Self-citationRNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Non-coding RNAs as regulators of gene expression and epigenetics
Kaikkonen, M. U., Lam, M. T. Y., & Glass, C. K. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr097 · Cited by 764
On the road to reading the RNA-interference code
Siomi, H., & Siomi, M. C. (2009) · Nature · doi:10.1038/nature07754 · Cited by 675
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Self-citationStructural variations and stabilising modifications of synthetic siRNAs in mammalian cells
Czauderna, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg393 · Cited by 623
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Off-target effects by siRNA can induce toxic phenotype
Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.28106 · Cited by 490
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R., & Kinch, M. S. (2001) · PubMed · Cited by 463
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Liposomal siRNA nanocarriers for cancer therapy
Ozpolat, B., Sood, A. K., & Lopez-Berestein, G. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.008 · Cited by 442
Self-citationMechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Targeted Quantum Dot Conjugates for siRNA Delivery
Derfus, A. M., Chen, A. A., Min, D.-H., Ruoslahti, E., & Bhatia, S. N. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060367e · Cited by 395
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Lee, J., Lee, K., Moon, S. H., Lee, Y., Park, T. G., & Cheon, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805998 · Cited by 365
Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes
Dokka, S., Toledo, D., Shi, X., Castranova, V., & Rojanasakul, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007504613351 · Cited by 349 · cited 2×
“Challenges observed in mouse models, such as dose-dependent hepatotoxicity, pulmonary inflammation and immune response, should be addressed before their translation into clinical trials [66,68].”
Chemical modification of siRNAs to improve serum stability without loss of efficacy
Choung, S., Kim, Y. J., Kim, S., Park, H.-O., & Choi, Y.-C. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.049 · Cited by 348
Spagnou, S., Miller, A. D., & Keller, M. (2004) · Biochemistry · doi:10.1021/bi048950a · Cited by 342
Minakuchi, Y. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh093 · Cited by 336
siRNA Selection Server: an automated siRNA oligonucleotide prediction server
Yuan, B., Latek, R., Hossbach, M., Tuschl, T., & Lewitter, F. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh366 · Cited by 307
Novel classes of non-coding RNAs and cancer
Sana, J., Faltejskova, P., Svoboda, M., & Slaby, O. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-103 · Cited by 304
Halder, J., Kamat, A. A., Landen, C. N., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0021 · Cited by 297
Self-citationQuantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference
Tan, W. B., Jiang, S., & Zhang, Y. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.018 · Cited by 295
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Altered gene expression in plants due totrans interactions between homologous genes
JORGENSEN, R. (1990) · Trends in Biotechnology · doi:10.1016/0167-7799(90)90220-r · Cited by 287
Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Han, H. D., Mangala, L. S., Lee, J. W., Shahzad, M. M. K., Kim, H. S., Shen, D., Nam, E. J., Mora, E. M., Stone, R. L., Lu, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0005 · Cited by 282
Self-citationOverexpression of the EphA2 tyrosine kinase in prostate cancer
Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J. S., Bostwick, D. G., Snyder, P., Kerns, B. J., Waters, D. J., & Kinch, M. S. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19991201)41:4<275::aid-pros8>3.0.co;2-t · Cited by 269
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.273 · Cited by 265
Lindberg, R. A., & Hunter, T. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6316 · Cited by 257
Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn024 · Cited by 257
Self-citationBiodistribution of phosphodiester and phosphorothioate siRNA
Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Öz, O. K., Mason, R. P., & Corey, D. R. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.074 · Cited by 251
Hess, A. R., Seftor, E. A., Gardner, L. M., Carles‐Kinch, K., Schneider, G. B., Seftor, R. E. B., Kinch, M. S., & Hendrix, M. J. C. (2001) · PubMed · Cited by 240
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.
Kinch, M. S., Moore, M.-B. H., & Harpole, D. H. (2003) · PubMed · Cited by 235
Nanomedicine based approaches for the delivery of siRNA in cancer
Ozpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 218
Self-citationFlenniken, A. M., Gale, N. W., Yancopoulos, G. D., & Wilkinson, D. G. (1996) · Developmental Biology · doi:10.1006/dbio.1996.0269 · Cited by 214
EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma
Thaker, P. H., Deavers, M., Celestino, J., Thornton, A., Fletcher, M. S., Landen, C. N., Kinch, M. S., Kiener, P. A., & Sood, A. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0589 · Cited by 211
Self-citationRNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
Zamora, M. R., Budev, M., Rolfe, M., Gottlieb, J., Humar, A., DeVincenzo, J., Vaishnaw, A., Cehelsky, J., Albert, G., Nochur, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201003-0422oc · Cited by 210
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K.-T., Burnett, J., & Rossi, J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 205
RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Kaiser, P. K., Symons, R. C. A., Shah, S. M., Quinlan, E. J., Tabandeh, H., Do, D. V., Reisen, G., Lockridge, J. A., Short, B., Guerciolini, R., et al. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.02.006 · Cited by 195
Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System
Pirollo, K. F., Rait, A., Zhou, Q., Hwang, S. H., Dagata, J. A., Zon, G., Hogrefe, R. I., Palchik, G., & Chang, E. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4535 · Cited by 195
Improved silencing properties using small internally segmented interfering RNAs
Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W., Ravindra Babu, B., Wengel, J., & Kjems, J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm548 · Cited by 192
siPools: highly complex but accurately defined siRNA pools eliminate off-target effects
Hannus, M., Beitzinger, M., Engelmann, J. C., Weickert, M.-T., Spang, R., Hannus, S., & Meister, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku480 · Cited by 178
Chen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176
Ui-Tei, K., Naito, Y., Zenno, S., Nishi, K., Yamato, K., Takahashi, F., Juni, A., & Saigo, K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn042 · Cited by 176
Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., Leslie, M. C., Vivas-Mejia, P. E., Lopez-Berestein, G., Sood, A. K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2397 · Cited by 163
Self-citationImproved and automated prediction of effective siRNA
Chalk, A. M., Wahlestedt, C., & Sonnhammer, E. L. L. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.181 · Cited by 160
Sequence characteristics of functional siRNAs
JAGLA, B., AULNER, N., KELLY, P. D., SONG, D., VOLCHUK, A., ZATORSKI, A., SHUM, D., MAYER, T., DE ANGELIS, D. A., OUERFELLI, O., et al. (2005) · RNA · doi:10.1261/rna.7275905 · Cited by 160
Fluiter, K. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg185 · Cited by 158
Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
Gray, M. J., Van Buren, G., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm279 · Cited by 158
Self-citationBartlett, D. W., & Davis, M. E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21285 · Cited by 153
Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs
Sioud, M., Furset, G., & Cekaite, L. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.177 · Cited by 151
Many commonly used siRNAs risk off-target activity
Snøve, O., & Holen, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.175 · Cited by 149
Wu, S. Y., Yang, X., Gharpure, K. M., Hatakeyama, H., Egli, M., McGuire, M. H., Nagaraja, A. S., Miyake, T. M., Rupaimoole, R., Pecot, C. V., et al. (2014) · Nature Communications · doi:10.1038/ncomms4459 · Cited by 146
Self-citationKim, H. R., Kim, I. K., Bae, K. H., Hyeon, L. S., Lee, Y., & Park, T. G. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000233 · Cited by 139
Strumberg, D., Schultheis, B. S., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J., & Drevs, J. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp50076 · Cited by 137
Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer
Landen, C. N., Lu, C., Han, L. Y., Coffman, K. T., Bruckheimer, E., Halder, J., Mangala, L. S., Merritt, W. M., Lin, Y. G., Gao, C., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj414 · Cited by 136
Self-citationActivation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade
Pratt, R. L., & Kinch, M. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205758 · Cited by 135
Overexpression of Protein Tyrosine Kinases in Human Esophageal Cancer
Nemoto, T., Ohashi, K., Akashi, T., Johnson, J. D., & Hirokawa, K. (2008) · Pathobiology · doi:10.1159/000164123 · Cited by 130
Differential Regulation of EphA2 in Normal and Malignant Cells
Walker‐Daniels, J., Hess, A. R., Hendrix, M. J. C., & Kinch, M. S. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63899-0 · Cited by 130
EphA2 overexpression is associated with angiogenesis in ovarian cancer
Lin, Y. G., Han, L. Y., Kamat, A. A., Merritt, W. M., Landen, C. N., Deavers, M. T., Fletcher, M. S., Urbauer, D. L., Kinch, M. S., & Sood, A. K. (2006) · Cancer · doi:10.1002/cncr.22415 · Cited by 122
Self-citationProtein tyrosine kinases in malignant melanoma
Easty, D. J., & Bennett, D. C. (2000) · Melanoma Research · doi:10.1097/00008390-200010000-00001 · Cited by 117
Yu, D., Peng, P., Dharap, S. S., Wang, Y., Mehlig, M., Chandna, P., Zhao, H., Filpula, D. R., Yang, K., Borowski, V., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.050 · Cited by 116
In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma
Martínez, T., González, M. V., Roehl, I., Wright, N., Pañeda, C., & Jiménez, A. I. (2013) · Molecular Therapy · doi:10.1038/mt.2013.216 · Cited by 116
Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery
Shen, H., Rodriguez‐Aguayo, C., Xu, R., González-Villasana, V., Mai, J., Huang, Y., Zhang, G., Guo, X., Bai, L., Qin, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2764 · Cited by 108
Self-citationTekedereli, İ., Alpay, S. N., Akar, U., Yuca, E., Ayugo-Rodriguez, C., Han, H.-D., Sood, A. K., Lopez‐Berestein, G., & Özpolat, B. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.45 · Cited by 106
Self-citationEphA2 as a target for ovarian cancer therapy
Landen, C. N., Kinch, M. S., & Sood, A. K. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.6.1179 · Cited by 99
Self-citationMulti-way clustering of microarray data using probabilistic sparse matrix factorization
Dueck, D., Morris, Q., & Frey, B. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti1041 · Cited by 98
Selective Protection of Nuclease-Sensitive Sites in siRNA Prolongs Silencing Effect
Volkov, A. A., Kruglova, N. S., Meschaninova, M. I., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0162 · Cited by 88
du Bois, A., Neijt, J. P., & Thigpen, J. T. (1999) · Annals of Oncology · doi:10.1023/a:1008355317514 · Cited by 85
Filtering of Ineffective siRNAs and Improved siRNA Design Tool
Yiu, S., Wong, P. W. H., Lam, T., Mui, Y.-C., Kung, H. F., Lin, M. C. M., & Cheung, Y.-T. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth498 · Cited by 81
Yan, Z., Tiller, P. R., Chen, I., Beverly, M. B., & Hochman, J. H. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3561 · Cited by 80
Designing highly active siRNAs for therapeutic applications
Walton, S. P., Wu, M., Gredell, J. A., & Chan, C. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07903.x · Cited by 78
for the PF-04523655 Study Group, Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., Chi-Burris, K., Yan, E., Paggiarino, D. A., et al. (2012) · Eye · doi:10.1038/eye.2012.106 · Cited by 70
Selection of hyperfunctional siRNAs with improved potency and specificity
Wang, X., Wang, X., Varma, R. K., Beauchamp, L., Magdaleno, S. M., & Sendera, T. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp864 · Cited by 70
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Han, L., Dong, Z., Qiao, Y., Kristensen, G. B., Holm, R., Nesland, J. M., & Suo, Z. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.036 · Cited by 68
Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors
Shao, L., Tekedereli, İ., Wang, J., Yuca, E., Tsang, S. V., Sood, A. K., Lopez‐Berestein, G., Özpolat, B., & Ittmann, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2715 · Cited by 62
Self-citationHogrefe, R. I., Lebedev, A. V., Zon, G., Pirollo, K. F., Rait, A. S., Zhou, Q., Yu, W., & Chang, E. H. (2006) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770600793885 · Cited by 56
Designing Functional siRNA with Reduced Off-Target Effects
Naito, Y., & Ui‐Tei, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_3 · Cited by 44
siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs
Hajeri, P. B., & Singh, S. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.001 · Cited by 42
Deciphering the Code of Innate Immunity Recognition of siRNAs
Sioud, M. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_2 · Cited by 39
Arlinghaus, R. B., Lopez‐Berestein, G., Belmont, J. W., Rosenblum, M. G., Sun, T., Stephens, C. L., Monaco, G., Gutiérrez-Puente, Y., & Tari, A. M. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1243 · Cited by 38
Self-citationDoes the understanding of immune activation by RNA predict the design of safe siRNAs?
Sioud, M. (2008) · Frontiers in bioscience · doi:10.2741/3011 · Cited by 35
Richardson, F. C., Tennant, B. C., Meyer, D. J., Richardson, K. A., Mann, P. C., Mcginty, G. R., Wolf, J. L., Zack, P. M., & Bendele, R. A. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700601 · Cited by 34
Designing effective siRNAs with off-target control
Snøve, O., Nedland, M., Fjeldstad, S. H., Humberset, H., Birkeland, O. R., Grünfeld, T., & Sætrom, P. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.097 · Cited by 28
Potential Design Rules and Enzymatic Synthesis of siRNAs
Sioud, M., & Leirdal, M. (2004) · Humana Press eBooks · doi:10.1385/1-59259-746-7:457 · Cited by 11
Cited by
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Metadata
- Authors
- Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 87
- Pages
- 108-119
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2098777190
- Cited by
- 449
- References
- 114
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.